Last reviewed · How we verify
AR101 powder provided in capsules
AR101 is an oral immunotherapy for peanut allergy.
AR101 is an oral immunotherapy for peanut allergy. Used for Peanut allergy.
At a glance
| Generic name | AR101 powder provided in capsules |
|---|---|
| Sponsor | Aimmune Therapeutics, Inc. |
| Drug class | oral immunotherapy |
| Modality | Biologic |
| Therapeutic area | Allergy |
| Phase | Phase 2 |
Mechanism of action
AR101 works by gradually increasing tolerance to peanut protein through the ingestion of small, controlled amounts of peanut flour. This is achieved through a process called desensitization, where the body becomes less reactive to the presence of peanuts over time.
Approved indications
- Peanut allergy
Common side effects
- Gastrointestinal symptoms
- Anaphylaxis
Key clinical trials
- Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (PHASE3)
- Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) (PHASE3)
- PALISADE Follow-on Study (ARC004) (PHASE3)
- Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT (PHASE2)
- Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (PHASE3)
- ARTEMIS Peanut Allergy In Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AR101 powder provided in capsules CI brief — competitive landscape report
- AR101 powder provided in capsules updates RSS · CI watch RSS
- Aimmune Therapeutics, Inc. portfolio CI